Bristol-Myers Squibb: all 2,184 studies

Page 19 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• Safety Study of BMS-823778 in Subjects With Type 2 DiabetesCompletedNCT01111955Phase 2
• Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTerminatedNCT01108705Phase 3
• Single Ascending Dose Study of BMS-820132 in Patients With Type 2 DiabetesCompletedNCT01105429Phase 1
• A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart FailureCompletedNCT01096043Phase 2
• Safety Study of Abatacept in SwedenCompletedNCT01094795
• Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart FailureCompletedNCT01092325Phase 1/2
• Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)Active, not recruitingNCT01088360
• Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)CompletedNCT01088321
• Abatacept Pregnancy Exposure RegistryCompletedNCT01087125
• Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal CancerCompletedNCT01086267Phase 1/2
• Safety Study of BMS-844421 for Treatment of HypercholesterolemiaTerminatedNCT01082562Phase 1
• Connect® MM- The Multiple Myeloma Disease RegistryTerminatedNCT01081028
• Connect™ CLL: The Chronic Lymphocytic Leukemia Disease RegistryCompletedNCT01081015
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163CompletedNCT01079819Phase 1
• Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerCompletedNCT01068704Phase 2
• Drug Interaction Oral Contraceptive Pill (OCP)CompletedNCT01063023Phase 1
• Safety Study of BMS-770767 in Subjects With HypercholesterolemiaCompletedNCT01058083Phase 2
• Multiple Dose Japanese Bridging StudyCompletedNCT01057030Phase 1
• An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) SubjectCompletedNCT01051414Phase 2
• Single Ascending Dose (BMS-813160) StudyCompletedNCT01049165Phase 1
• Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)CompletedNCT01046864Phase 1
• Safety Study of BMS-770767 in Subjects With Type 2 DiabetesCompletedNCT01046422Phase 2
• Drug-Drug Interaction Study With Aricept® (Donepezil)CompletedNCT01042314Phase 1
• Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)CompletedNCT01039194Phase 1
• Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine TherapyCompletedNCT01037166Phase 2
• An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B InfectionCompletedNCT01037062Phase 2
• Study of BMS-650032 With Peginterferon Alfa-2a Plus RibavirinCompletedNCT01030432Phase 2
• Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck CancerCompletedNCT01024101Phase 2
• Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01024062Phase 2
• Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast CancerCompletedNCT01023204Phase 2
• A Phase II Dose Response Study in Japan in Chronic Hepatitis BCompletedNCT01022801Phase 2
• A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B InfectionCompletedNCT01020565Phase 2
• Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032CompletedNCT01019070Phase 1
• Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in JapanCompletedNCT01018745Phase 1
• Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)CompletedNCT01017367Phase 2
• Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCompletedNCT01012895Phase 2
• Drug-Drug Interaction Study With RifampinCompletedNCT01002079Phase 1
• Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownNCT01001754Phase 2
• Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy SubjectsCompletedNCT00996879Phase 1
• A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)CompletedNCT00990912Phase 1/2
• Entecavir Plus Adefovir in Lamivudine-Resistant PatientsWithdrawnNCT00986778Phase 4
• Safety Study of BMS-816336 in Healthy Male SubjectsCompletedNCT00979368Phase 1
• Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsCompletedNCT00979316Phase 1
• A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedNCT00975767Phase 1
• Continue Entecavir Rollover From ChinaCompletedNCT00975091Phase 3
• Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C VirusCompletedNCT00971308Phase 1
• Single Dose Study of BMS-820836CompletedNCT00964912Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy SubjectsCompletedNCT00949767Phase 1
• Japanese Bridging Study Conducted in the United StatesWithdrawnNCT00947245Phase 1
• Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT00944905Phase 1
• Ex Vivo Human Thrombosis Chamber StudyCompletedNCT00935506Phase 1
• Long-term Data Collection for Subjects in MDX-010 StudiesCompletedNCT00928031
• A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung CancerCompletedNCT00927875Phase 1
• A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.CompletedNCT00915083Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese SubjectsCompletedNCT00909766Phase 1/2
• A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal AdenocarcinomasCompletedNCT00909402Phase 1
• Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCCCompletedNCT00908752Phase 3
• Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT00908024Phase 1/2
• Drug-Drug Interaction Study in Healthy SubjectsCompletedNCT00904059Phase 1
• Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's DiseaseCompletedNCT00901498Phase 1
• A Study of FV-100 Versus Valacyclovir in Patients With Herpes ZosterCompletedNCT00900783Phase 2
• Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in JapanCompletedNCT00898716Phase 1
• Multiple-Ascending Dose StudyCompletedNCT00892840Phase 1
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's DiseaseTerminatedNCT00890890Phase 2
• Multiple Ascending Dose (MAD) Combination in Subjects With Multiple MyelomaCompletedNCT00884546Phase 1
• Safety Study to Evaluate BMS-830216 in Healthy SubjectsCompletedNCT00878020Phase 1
• Study of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaWithdrawnNCT00872976Phase 1
• Drug-Drug Interaction (DDI) w/Ketoconazole or FluconazoleCompletedNCT00860275Phase 1
• First Line Hepato Cellular Carcinoma (HCC)CompletedNCT00858871Phase 3
• Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck CancerCompletedNCT00855764Phase 2
• Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal CancerCompletedNCT00851045Phase 2
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung CancerTerminatedNCT00850577Phase 2
• An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid MetabolismCompletedNCT00847782Not applicable
• A Study of BMS-863233 in Patients With Hematologic CancerTerminatedNCT00838890Phase 1/2
• Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy SubjectsCompletedNCT00836602Phase 1
• Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly JapaneseCompletedNCT00828646Phase 1
• Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib TreatmentCompletedNCT00825955Phase 3
• A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic MalignanciesWithdrawnNCT00820768Phase 1
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00810147Phase 2
• Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab TherapyCompletedNCT00803556Phase 1
• Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaWithdrawnNCT00803374Phase 1
• Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced CancersCompletedNCT00798252Phase 1
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00793897Phase 1
• Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced CancersWithdrawnNCT00792558Phase 1
• Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast CancerCompletedNCT00788333Phase 1/2
• Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast CancerTerminatedNCT00780000Phase 2
• Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating TanespimycinCompletedNCT00779428Phase 2
• Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed HerceptinCompletedNCT00773344Phase 1/2
• CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma MultiformeStatus unknownNCT00768911Phase 1
• Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
• A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCompletedNCT00743938Phase 2
• Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaWithdrawnNCT00732186Phase 1
• Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell LymphomaWithdrawnNCT00730652Phase 1
• Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00729950Phase 1
• Multiple Ascending Dose (MDX1105-01)CompletedNCT00729664Phase 1
• Drug Interaction Study With a Potential Alzheimer's Disease CompoundCompletedNCT00726726Phase 1
• A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00722358Phase 2
• A Belatacept Compassionate Use Study for Patients With a Kidney TransplantNo longer availableNCT00719225
• Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)TerminatedNCT00707590Phase 1
• A Study of MDX-1106 to Treat Patients With Hepatitis C InfectionCompletedNCT00703469Phase 1

← Bristol-Myers Squibb overview and focus areas